drugset / Trial / NCT07300267

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

NCT07300267

Phase 1 Recruiting 210 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria. This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.

Timeline

Start
2026-01-13
Primary completion
2028-10-24
Completion
2029-05-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator PCV20 Vaccine 0.5 ml Intramuscular
Subject V118C Vaccine 0.5 ml Intramuscular